| 초록 |
As countermeasures against the COVID-19 pandemic, numerous therapeutic agents and vaccines are being under developed. Among them, therapeutic antibodies have been considered as one of the most effective agents to treat patients with the early stage of SARS-CoV-2 infection. In this study, we have isolated human antibodies against the receptor binding domain (RBD) of SARS-CoV2 spike protein using our in-house-constructed human naïve antibody library. To improve antigen binding affinity and specificity of resulting anti-SARS-CoV-2 antibodies, various high throughput engineering strategies have been employed, and the results will be presented. In addition, considering emergence of multiple new SARS-CoV-2 variants that escape neutralization by developed-vaccine induced immunity and significantly reduce the potency of therapeutic agents, we are ongoing to evolve previously identified antibodies towards novel therapeutic agents with highly efficacious against an emerging SARS-CoV-2 variant. |
